Skip to main content
α
中文
Back to research

Thermo Fisher (TMO) stock analysis · Nov 2026

Updated regularlyUS stockHealthcare
Written Nov 9 (close at the time $694.76, 11/6)Latest close $669.54 (11/20)P/E (TTM) 35.3 · Next earnings 2027-01-28

At a glance

Key question: TMO's stock price has experienced a technical correction after breaking through the high of $704. Whether the contradiction between its weakened short-term momentum and high valuation will lead to a trend reversal.

Key research points

  • Key support level: $679.00 (the low on November 5, 2026 coincides with the middle track of the Bollinger Bands). If it falls below, it may open a channel down to $661.
  • First Resistance Level: $704.00 (historical high on October 15, 2026), which is the early pressure platform. Whether it is broken through or not will affect short-term direction judgment.
  • MACD indicator weakens: The latest value is 11.71, down from 13.23 the previous day. The histogram shrinks, showing that the upward momentum continues to weaken, and there is a risk of top divergence.
  • RSI fell back to the neutral range: 52.80, retracing from the overbought zone (>59), indicating that short-term bull power has weakened and there is a lack of clear upward momentum.
  • Long-term moving average is still strong: The current price is well above the 50-day average ($655.57) and the 200-day average ($550.97), and the mid- to long-term upward trend has not been destroyed.

Bull case

  • The mid- to long-term trend remains healthy, the stock price is significantly higher than the 50-day and 200-day moving averages, and the bull market structure has not been broken.
  • Free cash flow is strong, with TTM reaching US$6.442 billion, supporting dividends, repurchases and expansion investments, with fundamental support.
  • The forward price-to-earnings ratio (25.01) is below the industry average. Compared with the historical average, it has been restored and the valuation is more reasonable.

Cautious view

  • The PEG ratio is as high as 2.01, which is significantly higher than 1, reflecting that the stock price is rising faster than earnings growth, and there is a risk of a growth bubble.
  • The debt-to-equity ratio is 75.36%, the net debt/free cash flow is about 5.57 times, the financial leverage is high, and debt repayment pressure will appear when interest rates rise or the economy goes down.
  • The technical aspect shows signs of divergence from the top, with MACD and RSI weakening simultaneously, and short-term correction pressure is obvious.

Risks

  • Valuation Risk: Although the current forward-looking P/E ratio has fallen, the PEG ratio is too high. If future earnings growth is slower than expected, the valuation may be further pressured.
  • Financial Risk: The debt-to-equity ratio is relatively high. If financing costs increase or cash flow fluctuates, it may affect the stability of the capital structure.
  • Competitive Risk: Adjustments in the downstream semiconductor industry may be transmitted to the demand for electronic materials, affecting the company's core business income.
  • Event Risk: The upgrade of U.S. export control policies may restrict the supply chain layout of high-end chip-related materials.
  • Emotional Risk: The proportion of positive emotions on social media reached 67.3%, which is close to the historical peak. Once the good news is realized or negative news appears, it is easy to trigger a rapid correction.

Metrics to watch

  • Quarterly free cash flow: The latest period reached US$2.113 billion, an increase of 15% month-on-month. It is a key indicator to measure the improvement of operating efficiency and needs to be continuously tracked.
  • Gross profit margin and operating profit margin: currently are 14.94% and 20.19% respectively. If there is a continuous decline, it may reflect the weakening of cost-passing ability or the intensification of competition.
  • R&D expenditure as a proportion of revenue: If the proportion of R&D investment decreases, it may indicate that the strategic focus shifts to integration rather than innovation, affecting long-term competitiveness.
  • Federal Reserve Interest Rate Policy Trends: If interest rates remain high or are raised, it will increase the company's interest burden and affect net profit performance.
  • Overseas order implementation status: The actual execution progress of major orders such as Saudi Arabia's US$1.2 billion 5G contract will affect the market's confidence in the sustainability of growth.

Regularly updated · want it fresher? Sign up for 3 free on-demand reports

US, Hong Kong and China ADR names alike. Understand what happened to a company recently and why — the decision is yours.

This page is research and explanation. It is not directed at any individual's investment decision and is not investment advice. Investing involves risk.

Related: Healthcare

Other research in the same sector and market, to put TMO in context.

Abbott
ABT · Healthcare
Merck
MRK · Healthcare
Johnson & Johnson
JNJ · Healthcare
Pfizer
PFE · Healthcare
AbbVie
ABBV · Healthcare
Amgen
AMGN · Healthcare
See all 150 stock research pages → · Research hub · Earnings briefs